Go to
current issue
-
The power of three: hypofractionation, protons, and molecular imaging in glioblastoma radiotherapy Lancet Oncol. (IF 41.6) Pub Date : 2024-11-18 Eric A Mellon
No Abstract
-
Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment Lancet Oncol. (IF 41.6) Pub Date : 2024-11-18 Robin Forrest, Mylene Lagarde, Ajay Aggarwal, Huseyin Naci
BackgroundThe extent to which patients with cancer are willing to accept uncertainty about the clinical benefit of new cancer drugs in exchange for faster access is not known. This study aims to examine preferences for access versus certainty, and to understand factors that influence these preferences. MethodsA US nationally representative sample of older adults were recruited via Cint, an online platform
-
The trade-off between accelerated cancer drug approvals and patient preferences Lancet Oncol. (IF 41.6) Pub Date : 2024-11-18 Dario Trapani, Nirmala Bhoo-Pathy
No Abstract
-
Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial Lancet Oncol. (IF 41.6) Pub Date : 2024-11-18 Sujay Vora, Deanna Pafundi, Molly Voss, Matthew Buras, Jonathan Ashman, Bernard Bendok, William Breen, Leland Hu, Sani Kizilbash, Nadia Laack, Wei Liu, Anita Mahajan, Maciej Mrugala, Alyx Porter, Michael Ruff, Terence Sio, Joon Uhm, Ming Yang, Debra Brinkmann, Paul Brown
BackgroundOlder patients (aged ≥65 years) with glioblastoma have a worse prognosis than younger patients and a median overall survival of 6–9 months. 3,4-Dihydroxy-6-[18F]fluoro-L-phenylalanine (18F-DOPA) PET sensitively and specifically identifies metabolically active glioblastoma for preferential targeting. Proton beam therapy potentially improves quality of life (QOL) by sparing more healthy brain
-
Early switch maintenance in gastric cancer: who benefits most? Lancet Oncol. (IF 41.6) Pub Date : 2024-11-15 Tomoki Sakakida, Shigenori Kadowaki
No Abstract
-
The current and future global burden of cancer among adolescents and young adults: a population-based study Lancet Oncol. (IF 41.6) Pub Date : 2024-11-15 Taylor Hughes, Andrew Harper, Sumit Gupta, A Lindsay Frazier, Winette T A van der Graaf, Florencia Moreno, Adedayo Joseph, Miranda M Fidler-Benaoudia
BackgroundCompared with children and older adults, the burden of cancer in adolescents and young adults (ages 15–39) is understudied. We aimed to quantify the global burden of adolescent and young adult cancer in 2022 and 2050, and explore patterns in incidence, mortality, and case fatality. MethodsIn this population-based study, we used the GLOBOCAN database to quantify the number of new cases and
-
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial Lancet Oncol. (IF 41.6) Pub Date : 2024-11-15 Giovanni Randon, Sara Lonardi, Matteo Fassan, Federica Palermo, Stefano Tamberi, Elisa Giommoni, Carlotta Ceccon, Samantha Di Donato, Lorenzo Fornaro, Oronzo Brunetti, Ferdinando De Vita, Alessandro Bittoni, Claudio Chini, Andrea Spallanzani, Floriana Nappo, Valerie Bethaz, Antonia Strippoli, Tiziana Latiano, Giovanni Gerardo Cardellino, Francesco Giuliani, Filippo Pietrantonio
BackgroundPaclitaxel plus ramucirumab is recommended as a second-line treatment regimen in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer. We aimed to assess whether switch maintenance or early second-line therapy with paclitaxel plus ramucirumab improved outcomes compared with continuation of oxaliplatin and fluoropyrimidine doublet chemotherapy as a first-line
-
Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study Lancet Oncol. (IF 41.6) Pub Date : 2024-11-14 Sean Miller, Ralph Jiang, Matthew Schipper, Lars G Fritsche, Garth Strohbehn, Beth Wallace, Daria Brinzevich, Virginia Falvello, Benjamin H McMahon, Rafael Zamora-Resendiz, Nithya Ramnath, Xin Dai, Kamya Sankar, Donna M Edwards, Steven G Allen, Shinjae Yoo, Silvia Crivelli, Michael D Green, Alex K Bryant
BackgroundBlack patients were severely under-represented in the clinical trials that led to the approval of immune checkpoint inhibitors (ICIs) for all cancers. The aim of this study was to characterise the effectiveness and safety of ICIs in Black patients. MethodsWe did a retrospective cohort study of patients in the US Veterans Health Administration (VHA) system's Corporate Data Warehouse containing
-
Patients with head and neck cancer unfit for cisplatin—what next? Lancet Oncol. (IF 41.6) Pub Date : 2024-11-14 Naomi Kiyota
No Abstract
-
Retrospective analysis of immunotherapy outcomes in Black patients Lancet Oncol. (IF 41.6) Pub Date : 2024-11-14 Kerry L Reynolds, Pauline Funchain
No Abstract
-
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial Lancet Oncol. (IF 41.6) Pub Date : 2024-11-14 Loren K Mell, Pedro A Torres-Saavedra, Stuart J Wong, Julie A Kish, Steven S Chang, Richard C Jordan, Tian Liu, Minh Tam Truong, Eric W Winquist, Vinita Takiar, Trisha Wise-Draper, Jared R Robbins, Cristina P Rodriguez, Musaddiq J Awan, Beth M Beadle, Christina Henson, Samir Narayan, Sharon A Spencer, Steven Powell, Neal Dunlap, Quynh-Thu Le
BackgroundManagement of patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) when cisplatin is contraindicated is controversial. We aimed to assess whether radiotherapy with concurrent and adjuvant durvalumab would improve outcomes compared with radiotherapy with cetuximab. MethodsNRG-HN004 was designed as an open-label, multicentre, parallel-group, randomised, phase
-
UK Government introduces Tobacco and Vapes Bill Lancet Oncol. (IF 41.6) Pub Date : 2024-11-14 Talha Burki
No Abstract
-
Secondary cytoreductive surgery with HIPEC: a promising therapeutic option for recurrent ovarian cancer Lancet Oncol. (IF 41.6) Pub Date : 2024-11-14 Taymaa May
No Abstract
-
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial Lancet Oncol. (IF 41.6) Pub Date : 2024-11-14 Jean-Marc Classe, Pierre Meeus, Delphine Hudry, Romuald Wernert, François Quenet, Frédéric Marchal, Gilles Houvenaeghel, Anne-Sophie Bats, Fabrice Lecuru, Gwenaël Ferron, Cécile Brigand, Dominique Berton, Laurence Gladieff, Florence Joly, Isabelle Ray-Coquard, Sylvaine Durand-Fontanier, Gabriel Liberale, Marc Pocard, Constantin Georgeac, Sébastien Gouy, Olivier Glehen
BackgroundHyperthermic intraperitoneal chemotherapy (HIPEC) at interval cytoreductive surgery for ovarian cancer improves overall survival but its role in recurrent disease is uncertain. We aimed to compare outcomes in patients treated with or without HIPEC during surgery for recurrent ovarian cancer. MethodsThe multicentre, open-label, randomised, phase 3 CHIPOR trial was conducted at 31 sites in
-
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis Lancet Oncol. (IF 41.6) Pub Date : 2024-11-11 Luca Mastrantoni, Marta Chiaravalli, Alexia Spring, Viria Beccia, Armando Di Bello, Cinzia Bagalà, Maria Bensi, Diletta Barone, Giovanni Trovato, Giulia Caira, Giulia Giordano, Emilio Bria, Giampaolo Tortora, Lisa Salvatore
BackgroundIn advanced pancreatic ductal adenocarcinoma (PDAC), first-line chemotherapy is the standard of care. Due to the absence of head-to-head comparisons in clinical trials, we performed this systematic review and network meta-analysis to compare treatment options for PDAC in terms of their efficacy and toxicity. MethodsPubMed, the Cochrane Central Register of Controlled Trials, Embase, and oncological
-
Investing in cancer care in the UK: why aren't we acting on the evidence? Lancet Oncol. (IF 41.6) Pub Date : 2024-11-11 Zachary J Ward, Rifat Atun, Ajay Aggarwal, Mark Lawler, Hedvig Hricak
No Abstract
-
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial Lancet Oncol. (IF 41.6) Pub Date : 2024-11-07 Sai-Lan Liu, Xiao-Yun Li, Jin-Hao Yang, Dong-Xiang Wen, Shan-Shan Guo, Li-Ting Liu, Yi-Fu Li, Mei-Juan Luo, Si-Yi Xie, Yu-Jing Liang, Xue-Song Sun, Zhen-Chong Yang, Xiao-Fei Lv, Dong-Hua Luo, Ji-Bin Li, Qing Liu, Pan Wang, Ling Guo, Hao-Yuan Mo, Rui Sun, Hai-Qiang Mai
BackgroundPatients with locoregionally advanced nasopharyngeal carcinoma with a high pretreatment plasma concentration of Epstein–Barr virus (EBV) DNA remain at high risk for recurrence after concurrent chemoradiotherapy. This study aimed to compare the efficacy and safety of neoadjuvant–adjuvant treatment with the PD-1 inhibitor toripalimab and concurrent chemoradiotherapy versus placebo and concurrent
-
New Zealand doctors raise alarm about cancer drugs inequity Lancet Oncol. (IF 41.6) Pub Date : 2024-11-07 Tony Kirby
No Abstract
-
Impact of radiopharmaceutical shortage prompts questions on UK resilience Lancet Oncol. (IF 41.6) Pub Date : 2024-11-07 Emma Wilkinson
No Abstract
-
Locoregionally advanced nasopharyngeal carcinoma: integrating immunotherapy into definitive treatment Lancet Oncol. (IF 41.6) Pub Date : 2024-11-07 Dora L W Kwong
No Abstract
-
Group of UK MPs urge colleagues to support assisted dying bill Lancet Oncol. (IF 41.6) Pub Date : 2024-11-07 Sharmila Devi
No Abstract
-
Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types Lancet Oncol. (IF 41.6) Pub Date : 2024-11-04 Karl Semaan, Rashad Nawfal, Elizabeth Nally, Yelena Y Janjigian, Caroline Robert, Solange Peters, Thomas Powles, Toni K Choueiri
Section snippets Patients receiving subsequent therapyInitially, we assessed the number of patients in the control groups who underwent any subsequent treatment (including surgery, radiotherapy, or systemic therapy) after a disease-free survival event. Among the 15 perioperative ICI trials examined, only eight trials provided data on the number of patients receiving any subsequent therapy. In the melanoma
-
European Commission highlights policies to support return to work for patients with cancer and survivors Lancet Oncol. (IF 41.6) Pub Date : 2024-11-04 Talha Burki
No Abstract
-
Final phase of HPV vaccination campaign launched in Bangladesh Lancet Oncol. (IF 41.6) Pub Date : 2024-11-04 Udani Samarasekera
No Abstract
-
Correction to Lancet Oncol 2024; 25: 1188–201 Lancet Oncol. (IF 41.6) Pub Date : 2024-10-30
Karpinski MJ, Hüsing J, Claassen K, et al Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol 2024; 25: 1188–201—The appendix of this Article has been corrected as of Oct 30, 2024.
-
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study Lancet Oncol. (IF 41.6) Pub Date : 2024-10-29 Dai Maruyama, Eric Jacobsen, Pierluigi Porcu, Pamela Allen, Kenji Ishitsuka, Shigeru Kusumoto, Tomoko Narita, Kensei Tobinai, Francine Foss, Kunihiro Tsukasaki, Tatyana Feldman, Yoshitaka Imaizumi, Koji Izutsu, Satoko Morishima, Nobuhiko Yamauchi, Junichiro Yuda, Jonathan E Brammer, Toyotaka Kawamata, Jia Ruan, Kisato Nosaka, Steven M Horwitz
BackgroundFew treatment options exist for patients with non-Hodgkin lymphoma, and outcomes remain poor for relapsed or refractory disease. We evaluated the safety and preliminary clinical activity of valemetostat, a novel inhibitor of EZH2 and EZH1, in patients with relapsed or refractory non-Hodgkin lymphomas. MethodsThis first-in-human, multicentre, open-label, single-arm, phase 1, dose-escalation
-
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study Lancet Oncol. (IF 41.6) Pub Date : 2024-10-29 Pier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, Stefan K Barta, Kenji Ishitsuka, Raul Córdoba, Shigeru Kusumoto, Emmanuel Bachy, Kate Cwynarski, Giuseppe Gritti, Anca Prica, Eric Jacobsen, Tatyana Feldman, Yann Guillermin, Daisuke Ennishi, Dok Hyun Yoon, Eva Domingo Domenech, Jasmine Zain, Jie Wang, Jin Seok Kim, Steven M Horwitz
BackgroundPeripheral T-cell lymphomas are aggressive non-Hodgkin lymphomas with few treatment options for relapsed or refractory disease. Valemetostat tosylate (valemetostat) is a potent, novel, dual inhibitor of EZH2 and EZH1. We investigated the clinical activity and safety of valemetostat in patients with relapsed or refractory peripheral T-cell lymphoma, and its safety in patients with relapsed
-
Caring for carers of people with cancer Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 The Lancet Oncology
No Abstract
-
The state of the science of oral selective oestrogen receptor degraders Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Kristina Fanucci, Erica L Mayer
No Abstract
-
Celiac plexus radiosurgery for retroperitoneal pain syndrome Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Ertugrul Senturk, Serap Catli Dinc
No Abstract
-
Celiac plexus radiosurgery for retroperitoneal pain syndrome – Authors' reply Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Yaacov R Lawrence, Ronen Fluss, Laurence S Freedman, Zvi Symon
No Abstract
-
Site-specific or empirical chemotherapy for cancer of unknown primary: the right answer? Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Ryan Huey, Kanwal Raghav
No Abstract
-
Site-specific or empirical chemotherapy for cancer of unknown primary: the right answer? – Authors' reply Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Xichun Hu, Shiyu Jiang, Xin Liu
No Abstract
-
PSMA-PET research: addressing challenges and prospects Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Hantong Hu
No Abstract
-
PSMA-PET research: addressing challenges and prospects Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Dan Shan
No Abstract
-
PSMA-PET research: addressing challenges and prospects – Authors' reply Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Boris A Hadaschik, Madeleine J Karpinski, Johannes Hüsing, Wolfgang P Fendler
No Abstract
-
Concerns regarding the AtTEnd trial in advanced endometrial carcinoma Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Queran Lin, Wenyi Jin, Dan Shan
No Abstract
-
Concerns regarding the AtTEnd trial in advanced endometrial carcinoma Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Ze Xiang, Jian Wu
No Abstract
-
Concerns regarding the AtTEnd trial in advanced endometrial carcinoma – Authors' reply Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Elena Biagioli, Eliana Rulli, Roldano Fossati, Nicoletta Colombo
No Abstract
-
Omitting study limitations might have implications for the patients Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Paul de Boissieu, Sylvie Chevret
No Abstract
-
Omitting study limitations might have implications for the patients – Authors' reply Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Jean-Yves Blay, Sylvie Chabaud, David Perol, Axel Le Cesne
No Abstract
-
[18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Xiaoling Xu, Lisha Ye, Jinpeng Shi, Huihui Li, Yong Fang
No Abstract
-
[18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Sarah Bowen Jones, Saskia Cooke, José Belderbos, Corinne Faivre-Finn
No Abstract
-
[18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer – Authors' reply Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Sébastien Thureau, Philippe Giraud, Gérard Zalcman, Pierre Vera
No Abstract
-
Correction to Lancet Oncol 2024; 25: 1325–36 Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28
Iliopoulos O, Iversen AB, Narayan V, et al. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol 2024; 25: 1325–36—In this Article, the second sentence in the fifth paragraph of the Results section, should read “After initiating belzutifan treatment, one patient (2%) underwent two CNS-related
-
Correction to Lancet Oncol 2024; 25: 1453–64 Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28
No Abstract
-
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Mafalda Oliveira MD, Denys Pominchuk PhD, Prof Zbigniew Nowecki MD, Erika Hamilton MD, Yaroslav Kulyaba MD, Timur Andabekov PhD, Prof Yevhen Hotko MD, Tamar Melkadze MD, Prof Gia Nemsadze MD, Prof Patrick Neven MD, Vladimir Vladimirov MD, Claudio Zamagni MD, Hannelore Denys MD, Frédéric Forget MD, Zsolt Horvath MD, Alfiya Nesterova MD, Maxine Ajimi PhD, Bistra Kirova MBChB, Teresa Klinowska PhD, Justin
Resistance to endocrine therapies in hormone receptor-positive breast cancer is challenging. We aimed to assess the next-generation oral selective oestrogen receptor degrader (SERD) and complete oestrogen receptor antagonist, camizestrant, versus the first-approved SERD, fulvestrant, in post-menopausal women with oestrogen receptor-positive, HER2-negative, advanced breast cancer.
-
Ischaemic cardiotoxicity of aromatase inhibitors in postmenopausal patients with early breast cancer in Denmark: a cohort study of real-world data Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Marie Lund PhD, Giulia Corn PhD, Maj-Britt Jensen MSc, Tonny Petersen PhD, Prof Kim Dalhoff DMSc, Prof Bent Ejlertsen DMSc, Prof Lars Køber DMSc, Jan Wohlfahrt DMSc, Prof Mads Melbye DMSc
For aromatase inhibitor treatment (AIT) in breast cancer, there is an unresolved concern about ischaemic cardiotoxicity. We investigated the association between AIT and ischaemic cardiotoxicity in a prospective cohort of female patients with early breast cancer who received contemporary treatment in Denmark.
-
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancements Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Javier E Villanueva-Meyer MD, Spyridon Bakas PhD, Pallavi Tiwari PhD, Prof Janine M Lupo PhD, Evan Calabrese MD PhD, Prof Christos Davatzikos PhD, Wenya Linda Bi MD PhD, Marwa Ismail PhD, Hamed Akbari MD PhD, Philipp Lohmann PhD, Thomas C Booth MD, Benedikt Wiestler MD, Prof Hugo J W L Aerts PhD, Ghulam Rasool PhD, Prof Joerg C Tonn MD, Prof Martha Nowosielski PhD, Prof Rajan Jain MD, Prof Rivka R
The development, application, and benchmarking of artificial intelligence (AI) tools to improve diagnosis, prognostication, and therapy in neuro-oncology are increasing at a rapid pace. This Policy Review provides an overview and critical assessment of the work to date in this field, focusing on diagnostic AI models of key genomic markers, predictive AI models of response before and after therapy,
-
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice Lancet Oncol. (IF 41.6) Pub Date : 2024-10-28 Spyridon Bakas PhD, Prof Philipp Vollmuth MD MBA, Prof Norbert Galldiks MD, Thomas C Booth MD PhD, Hugo J W L Aerts PhD, Wenya Linda Bi MD PhD, Benedikt Wiestler MD PhD, Pallavi Tiwari PhD, Sarthak Pati MSc, Ujjwal Baid PhD, Evan Calabrese MD PhD, Philipp Lohmann PhD, Martha Nowosielski MD PhD, Prof Rajan Jain MD, Prof Rivka Colen MD, Marwa Ismail PhD, Ghulam Rasool PhD, Prof Janine M Lupo PhD, Hamed
Technological advancements have enabled the extended investigation, development, and application of computational approaches in various domains, including health care. A burgeoning number of diagnostic, predictive, prognostic, and monitoring biomarkers are continuously being explored to improve clinical decision making in neuro-oncology. These advancements describe the increasing incorporation of artificial
-
Correction to Lancet Oncol 2024; 25: 1176–87 Lancet Oncol. (IF 41.6) Pub Date : 2024-10-25
Vera P, Thureau S, Le Tinier F, et al. Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial. Lancet Oncol 2024; 25: 1176–87—In this Article, Pierre Boissellier should have been spelled Pierre Boisselier
-
New funding for Indigenous-led cancer research and nationwide clinical trials in Australia Lancet Oncol. (IF 41.6) Pub Date : 2024-10-24 Tony Kirby
No Abstract
-
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis Lancet Oncol. (IF 41.6) Pub Date : 2024-10-19 Antonio D'Alessio MD, Bernardo Stefanini MD, Julia Blanter MD, Benjamin Adegbite MD, Fionnuala Crowley MD, Vincent Yip MD, Sarah Slater MD, Claudia Angela Maria Fulgenzi MD, Ciro Celsa MD PhD, Giulia Francesca Manfredi MD, Madhava Pai MD, Prof Robert D Goldin MD, Stephen C Ward MD PhD, Maria Isabel Fiel MD, Daniel H Shu MD, Yung-Yeh Su MD PhD, Alessio Cortellini MD PhD, Marina Baretti MD, Robert Anders
Neoadjuvant use of immune checkpoint inhibitors (ICIs) before liver resection results in pathological tumour regression in patients with hepatocellular carcinoma. We aimed to describe the characteristics of pathological responses after preoperative ICI therapy for hepatocellular carcinoma and to evaluate the association between the depth of tumour regression and relapse-free survival.
-
Renewed collaboration aims to improve cancer outcomes in South America Lancet Oncol. (IF 41.6) Pub Date : 2024-10-17 Manjulika Das
No Abstract
-
Cancer control in the Commonwealth: a roadmap Lancet Oncol. (IF 41.6) Pub Date : 2024-10-17 Rifat Atun, Bhawna Sirohi, Che Reddy, Mary Gospodarowicz
No Abstract
-
US legislation might soon allow easier access to cancer medications Lancet Oncol. (IF 41.6) Pub Date : 2024-10-17 Karl Gruber
No Abstract
-
Access to diagnostic imaging and radiotherapy technologies for patients with cancer in the Baltic countries, eastern Europe, central Asia, and the Caucasus: a comprehensive analysis Lancet Oncol. (IF 41.6) Pub Date : 2024-10-16 Prof Manjit Dosanjh PhD, Prof Vesna Gershan PhD, Eugenia C Wendling BSc, Prof Jamal S Khader MD, Taofeeq A Ige PhD, Prof Mimoza Ristova PhD, Richard Hugtenburg PhD, Petya Georgieva MSc, C Norman Coleman MD, David A Pistenmaa MD, Gohar H Hovhannisyan PhD, Prof Tatul Saghatelyan MD, Prof Kamal Kazimov MD, Prof Rovshan Rzayev PhD, Gulam R Babayev PhD, Mirzali M Aliyev MSc, Eduard Gershkevitsh PhD, Prof
Only 10–40% of patients with cancer in low-income and middle-income countries were able to access curative or palliative radiotherapy in 2015. We aimed to assess the current status of diagnostic imaging and radiotherapy services in the Baltic countries, eastern Europe, central Asia, and the Caucasus by collecting and analysing local data.
-
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial Lancet Oncol. (IF 41.6) Pub Date : 2024-10-14 Prof Mariano Provencio MD, Ernest Nadal MD, Amelia Insa, Rosario García Campelo MD, Joaquín Casal MD, Manuel Dómine MD, Bartomeu Massuti MD, Margarita Majem MD, Delvys Rodríguez-Abreu MD, Alex Martínez-Martí MD, Javier de Castro MD, David Gómez de Antonio MD, Iván Macia MD, Santiago Figueroa MD, Luís Fernández Vago MD, Virginia Calvo MD, Ramón Palmero MD, Belén Sierra-Rodero MSc, Cristina Martínez-Toledo
Perioperative immunotherapy improves short-term outcomes in resectable non-small-cell lung cancer (NSCLC). We now report 5-year survival from the NADIM trial to assess its long-term benefit.
-
Interchangeability of immune checkpoint inhibitors: an urgent need for action Lancet Oncol. (IF 41.6) Pub Date : 2024-10-14 Michiel Zietse PharmD, Roelof W F van Leeuwen PhD, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani PhD, Jolanda E de Boer MSc, Rudy Dupree MSc, Prof Ron H J Mathijssen MD, Lonneke Timmers PhD
Prevailing uncertainties regarding the therapeutic interchangeability of PD-1 and PD-L1 inhibitors affect both clinical decision making and health-care budgeting. This Personal View presents a comprehensive assessment of the fragmented regulatory landscape of PD-1 and PD-L1 inhibitors, highlighting the complex dynamics of market competition, pricing, and the effect on health-care budgets. Our paper
-
Correction to Lancet Oncol 2024; 25: 1310–24 Lancet Oncol. (IF 41.6) Pub Date : 2024-10-11
Wang ES, Issa GC, Erba HP, et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol 2024; 25: 1310–24—In this Article, the colours in the key for ziftomenib 200 mg and ziftomenib 600 mg in figure 2B were switched. This correction has been made to the online version as of Oct 11, 2024.
更新日期：2024-11-15
Copyright © 2014-2024 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号